Ocular Science Medical Advisory Board Expands to 28 Leaders in Ophthalmology and Optometry from Around the Country

Jacqueline Griffiths joins the biotech’s leadership team

EL SEGUNDO, Calif. (May 12, 2022) – Southern California biotech Ocular Science has expanded its national medical advisory board to 28 ophthalmologists and optometrists. Jacqueline Griffiths, MD, with nearly 30 years of experience, is joining a board that establishes strategies to focus on enhanced clinical solutions, products and patient outcomes for Ocular Science and affiliated PCAB-accredited 503A compounding pharmacy, OSRX®.

Dr. Griffiths, repeatedly voted “Top Ophthalmologist” by the Washington Post, Northern Virginia Magazine and Washingtonian Magazine, founded the first and only Laser Eye Center in Reston, Va., in 1999. She specializes in cataract and refractive surgery and is one of the few women- and minority-owned laser centers in the world. (For full bios, visit

“The Ocular Science medical advisory board has an unmatched range of voices, talents and expertise. It’s the who’s who of ophthalmology, serving as our sounding board for nascent research and medical advances,” says Anthony Sampietro, founder and CEO of Ocular Science.  “We have rare access to brilliant minds that shepherd our organization and have helped Ocular Science and its affiliate, OSRX, experience record financial growth for five consecutive years.”

OSRX, an Ocular Science affiliate, is a 503A compounding pharmacy that compounds customized (OMNI by OSRX®) ophthalmic medications that are patient-specific and have been prescribed for surgical vision correction, myopia and glaucoma management. OSRX combines multiple medications into a single bottle to provide patients with improved convenience, simplicity and affordability by reducing dosing complexity.

“I’m honored to be included with a remarkable collection of doctors who are members of the medical advisory board,” said Dr. Griffiths. “I look forward to being part of the Ocular Science family and to the continued success and growth of a great company.”


Ocular Science®, headquartered in El Segundo, Calif., was founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company is guided by a medical advisory board of world leaders in ophthalmology and focuses on the production, marketing and sales of compounded ophthalmic products. OSRX® – an affiliate of Ocular Science – is a PCAB-accredited 503A compounding pharmacy located in Missoula, Mont. that prepares customized medications in four areas of ophthalmology.

OSRX operates in compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.